Unlock stock picks and a broker-level newsfeed that powers Wall Street.
OTC Markets OTCPK - Delayed Quote USD

Laboratorios Farmaceuticos Rovi, S.A. (LABFF)

Compare
90.61
0.00
(0.00%)
At close: April 4 at 4:00:00 PM EDT
Loading Chart for LABFF
  • Previous Close 0.00
  • Open 90.61
  • Bid 51.08 x 36200
  • Ask 56.08 x 21500
  • Day's Range 90.61 - 90.61
  • 52 Week Range 86.05 - 90.61
  • Volume 100
  • Avg. Volume 0
  • Market Cap (intraday) 4.635B
  • Beta (5Y Monthly) 0.47
  • PE Ratio (TTM) 28.95
  • EPS (TTM) 3.13
  • Earnings Date May 8, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date Jul 8, 2024
  • 1y Target Est --

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi. In addition, the company offers contract-manufacturing services comprising compounding, aseptic filling and terminal sterilisation, inspection, installation of safety devices, labelling, packaging, serialisation and aggregation, for different injectable pharmaceutical forms, such as prefilled syringes, vials and cartridges, as well as manufacturing and packaging services for solid products. Its products are used for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. The company was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.

www.rovi.es

2,197

Full Time Employees

December 31

Fiscal Year Ends

Recent News: LABFF

View More

Performance Overview: LABFF

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is IBEX 35... (^IBEX) .

YTD Return

LABFF
0.00%
IBEX 35... (^IBEX)
7.67%

1-Year Return

LABFF
6.60%
IBEX 35... (^IBEX)
12.00%

3-Year Return

LABFF
104.44%
IBEX 35... (^IBEX)
45.78%

5-Year Return

LABFF
66.10%
IBEX 35... (^IBEX)
88.74%

Compare To: LABFF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: LABFF

View More

Valuation Measures

Annual
As of 4/4/2025
  • Market Cap

    2.77B

  • Enterprise Value

    2.87B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.92%

  • Return on Assets (ttm)

    13.69%

  • Return on Equity (ttm)

    24.33%

  • Revenue (ttm)

    763.75M

  • Net Income Avi to Common (ttm)

    136.88M

  • Diluted EPS (ttm)

    3.13

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    28.02M

  • Total Debt/Equity (mrq)

    19.67%

  • Levered Free Cash Flow (ttm)

    44.63M

Research Analysis: LABFF

View More

Company Insights: LABFF

Research Reports: LABFF

View More

People Also Watch